Global Botulinum Toxin Market to Reach US$4.3 Billion by 2018, According to New Report by Global Industry Analysts, Inc.

Share Article

GIA announces the release of a comprehensive global report on Botulinum Toxin markets. The world market for Botulinum Toxin is forecast to reach US$4.3 billion by the year 2018, stimulated by sustained dominance of existing BTX options, technological advancements, rising product approvals and increasing popularity of anti-aging products. Additionally, spate of new drug developments for both cosmetic and therapeutic indications, sustained demand from traditional market leaders such as the US and Europe and foray into relatively unexplored developing markets will provide the required zest and energy to drive home substantial gains.

Botulinum Toxin: A Global Strategic Business Report

Follow us on LinkedIn – Advancements in research and development of botulinum toxin has revolutionized its medical and therapeutic uses over the last few decades. However, clearly the largest strides have been taken in the field of facial aesthetics. Gains in this sphere have been spurred by a rich combination of scientific benefits, and market driven factors, such as, rising consumer disposable income, increased per capita spends on appearance enhancing products and solutions, growing social acceptance of aesthetic medical procedures, and easy product accessibility. With cosmetic indications for BTX ranging from facial wrinkles to eyebrow furrows, the rapidly aging world population emerges as a strong demographic driver of growth. In the field of neuromuscular therapeutics, use of botulinum toxin is driven by escalating incidences of movement related disorders and growing number of patients with muscle spasms. Further, expanding use of botulinum toxin (BTX) in medical aesthetic applications, in addition to other medical applications such as in neuromuscular indications, is helping drive demand in the international market.

The promising clinical trials of botulinum toxin drugs for indications such as pain management, asthma, primary and secondary focal dystonia and spasticity is anticipated to further boost sales of Off-Label BTX products. With a deficiency of suitable therapies, these under-treated conditions represent a huge and lucrative market for the BT drugs makers. In addition, unwavering focus on research and development of new treatment indications and unique non-injectable alternatives for botulinum toxin will further expand application possibilities, and the market’s revenue generating potential. Strengthening pipeline, together with growing off-label use extend hopes for a bullish long-term outlook.

Given the high patient expectations and demand in the cosmetic applications segment, growing instances of undesirable side effects have the potential to jeopardize the market’s prospects. Although side-effects associated with the use of botulinum toxin injections are rare, the threat has been gaining in magnitude over the last few years with growing off-label uses and rising instances of drug administration by non-qualified professionals. The likelihood of patients developing short-term side effects rises when treatment is administered by under-informed and unskilled healthcare practitioner. An inherent risk associated with both cosmetic and therapeutic botulinum toxin is the high risk of developing immunogenicity, even at low dosage. In a bid to deflect the heat generated by controversies surrounding immunogenicity, manufacturers are presently researching the possibility of reducing the protein load, a primary catalyst of immunogenicity, in the compound.

Botulinum toxin in currently the mainstay of developed regions such as the US and Europe and the leadership dominance is likely to continue over the next few years. The claim is well supported by the fact that maximum number of approvals for botulinum toxin products for several new indications have been obtained in these regions providing the platform for a robust future growth. The United States alone emerges as the single largest regional market, currently accounting for the lion’s share of the global Botulinum Toxin market for both therapeutic and cosmetic indications. The region is also expected to maintain a rapid development pace, surging ahead at the overall fastest CAGR of 10.7% through 2018. The development of new technologically advanced drugs and products, followed by continuous innovations in treatment procedures, is driving the US cosmetic therapies market by leaps and bounds.

In Europe, zeal for beauty is significantly raising the demand for Botox products. In the long-term, emerging nations of Asia-Pacific, Latin America, Eastern Europe and to some extent Middle East are expected to develop as lucrative future markets for botulinum toxin. However, it is still early days for these evolving markets and with few major drug developments on the anvil in the near term, it would still take time to be completely on par with the mature markets of US and Europe who already have years of experience, technology, infrastructure and financial backing as added advantage.

The worldwide botulinum toxin Therapeutics market represents the largest application segment in the global market for botulinum toxin and is set to grow exponentially at an impressive rate of over 10% through the analysis period due to the prophylactic and lifestyle-enhancing nature of the drug as well as the localized application of the treatment. The cosmetic application segment for botulinum toxin offers sturdy growth promise as well. The fear of aging has brought anti-aging products and technologies into the trading range. Growing awareness over the potential use and benefits of botulinum toxin among the aging patient population, over the last few years, has accelerated the acceptance of botulinum toxin based cosmetic procedures.

The US company, Allergan Inc., dominates the botulinum toxin arena with its brand Botox®, commanding a major chunk of the world market. Once a lone player in the market, Allergan’s Botox is facing increasing competition in the two application markets it serves – therapeutics and cosmetics. Other major players operating in the botulinum toxin market include, Ipsen Group, Lanzhou Institute of Biological Products, Metabiologics, Inc., Merz Pharma GmbH & Co., KGaA, Mentor Corporation, Medy-Tox Incorporated, Medicis Pharmaceutical Corporation, Revance Therapeutics, Inc., and US WorldMeds.

The research report titled “Botulinum Toxin: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive market overview, current market trends and issues, product and industry dynamics, key growth drivers, recent industry activity, and profiles of major/niche global market participants. The report provides annual sales estimates and projections for the years 2010 through 2018 in value (US$) terms for select geographic markets including, US, Europe and Rest of World. Key application segments analyzed include Cosmetic and Therapeutic The study also provides historic data for an insight into market evolution over the period 2004 through 2009.

For more details about this comprehensive market research report, please visit –
http://www.strategyr.com/Botulinum_Toxin_Market_Report.asp

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.

Follow us on LinkedIn

Global Industry Analysts, Inc.
Telephone: 408-528-9966
Fax: 408-528-9977
Email: press(at)StrategyR(dot)com
Web Site: http://www.StrategyR.com/

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Public Relations
Visit website